Johannes W. J. Bijlsma

Johannes W. J. Bijlsma

Auto-generated profile, based on publicly available information

Johannes W. J. Bijlsma

Department of Rheumatology and Clinical Immunology, University Medical Center, Utrecht, The Netherlands

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2011 in The Lancet
Verified
Journal Article
Closed access
JBJohannes Wj Bijlsma
Johannes Wj Bijlsma
FBFrancis Berenbaum
Francis Berenbaum
FLFloris Pjg Lafeber
Floris Pjg Lafeber

1 October 2021 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
Elena NikiphorouElena Nikiphorou
Elena Nikiphorou
ESEduardo Santos
Eduardo Santos
AMAndréa Marques
Andréa Marques
PBPeter Böhm
Peter Böhm
JBJohannes Wj Bijlsma
Johannes Wj Bijlsma
ABAilsa Bosworth
Ailsa Bosworth
Background An important but often insufficient aspect of care in people with inflammatory arthritis (IA) is empowering patients to acquire a good understanding of their disease and building their ability to deal effectively with the practical, physical and psychological impacts of it. Self-management skills can be helpful in this regard. Objectives To develop recommendations for the implementation of self-management strategies in IA. Methods A multidisciplinary taskforce of 18 members from 11 European countries was convened. A systematic review and other supportive information (survey of healthcare professionals (HCPs) and patient organisations) were used to formulate the recommendations. Results Three overarching principles and nine recommendations were formulated. These focused on empowering patients to become active partners of the team and to take a more proactive role. The importance of patient education and key self-management interventions such as problem solving, goal setting and cognitive behavioural therapy were highlighted. Role of patient organisations and HCPs in promoting and signposting patients to available resources has been highlighted through the promotion of physical activity, lifestyle advice, support with mental health aspects and ability to remain at work. Digital healthcare is essential in supporting and optimising self-management and the HCPs need to be aware of available resources to signpost patients. Conclusion These recommendations support the inclusion of self-management advice and resources in the routine management of people with IA and aim to empower and support patients and encourage a more holistic, patient-centred approach to care which could result in improved patient experience of care and outcomes.

1 January 2022 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
György NagyGyörgy Nagy
György Nagy
NRNadia M T Roodenrijs
Nadia M T Roodenrijs
PWPaco M J Welsing
Paco M J Welsing
MKMelinda Kedves
Melinda Kedves
AHAttila Hamar
Attila Hamar
JLJacob M van Laar
Jacob M van Laar
Objective To develop evidence-based European Alliance of Associations for Rheumatology (EULAR) points to consider (PtCs) for the management of difficult-to-treat rheumatoid arthritis (D2T RA). Methods An EULAR Task Force was established comprising 34 individuals: 26 rheumatologists, patient partners and rheumatology experienced health professionals. Two systematic literature reviews addressed clinical questions around diagnostic challenges, and pharmacological and non-pharmacological therapeutic strategies in D2T RA. PtCs were formulated based on the identified evidence and expert opinion. Strength of recommendations (SoR, scale A–D: A typically consistent level 1 studies and D level 5 evidence or inconsistent studies) and level of agreement (LoA, scale 0–10: 0 completely disagree and 10 completely agree) of the PtCs were determined by the Task Force members. Results Two overarching principles and 11 PtCs were defined concerning diagnostic confirmation of RA, evaluation of inflammatory disease activity, pharmacological and non-pharmacological interventions, treatment adherence, functional disability, pain, fatigue, goal setting and self-efficacy and the impact of comorbidities. The SoR varied from level C to level D. The mean LoA with the overarching principles and PtCs was generally high (8.4–9.6). Conclusions These PtCs for D2T RA can serve as a clinical roadmap to support healthcare professionals and patients to deliver holistic management and more personalised pharmacological and non-pharmacological therapeutic strategies. High-quality evidence was scarce. A research agenda was created to guide future research.

31 December 2021 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
PMPedro M Machado
Pedro M Machado
SLSaskia Lawson-Tovey
Saskia Lawson-Tovey
ASAnja Strangfeld
Anja Strangfeld
EMElsa F Mateus
Elsa F Mateus
KHKimme L Hyrich
Kimme L Hyrich
XMXavier Mariette
Xavier Mariette
Objectives To describe the safety of vaccines against SARS-CoV-2 in people with inflammatory/autoimmune rheumatic and musculoskeletal disease (I-RMD). Methods Physician-reported registry of I-RMD and non-inflammatory RMD (NI-RMDs) patients vaccinated against SARS-CoV-2. From 5 February 2021 to 27 July 2021, we collected data on demographics, vaccination, RMD diagnosis, disease activity, immunomodulatory/immunosuppressive treatments, flares, adverse events (AEs) and SARS-CoV-2 breakthrough infections. Data were analysed descriptively. Results The study included 5121 participants from 30 countries, 90% with I-RMDs (n=4604, 68% female, mean age 60.5 years) and 10% with NI-RMDs (n=517, 77% female, mean age 71.4). Inflammatory joint diseases (58%), connective tissue diseases (18%) and vasculitis (12%) were the most frequent diagnostic groups; 54% received conventional synthetic disease-modifying antirheumatic drugs (DMARDs), 42% biological DMARDs and 35% immunosuppressants. Most patients received the Pfizer/BioNTech vaccine (70%), 17% AstraZeneca/Oxford and 8% Moderna. In fully vaccinated cases, breakthrough infections were reported in 0.7% of I-RMD patients and 1.1% of NI-RMD patients. I-RMD flares were reported in 4.4% of cases (0.6% severe), 1.5% resulting in medication changes. AEs were reported in 37% of cases (37% I-RMD, 40% NI-RMD), serious AEs in 0.5% (0.4% I-RMD, 1.9% NI-RMD). Conclusion The safety profiles of SARS-CoV-2 vaccines in patients with I-RMD was reassuring and comparable with patients with NI-RMDs. The majority of patients tolerated their vaccination well with rare reports of I-RMD flare and very rare reports of serious AEs. These findings should provide reassurance to rheumatologists and vaccine recipients and promote confidence in SARS-CoV-2 vaccine safety in I-RMD patients.

1 February 2007 in Best Practice & Research Clinical Rheumatology
Verified
Journal Article
Closed access
JBJ.W.J. Bijlsma
J.W.J. Bijlsma
KKK. Knahr
K. Knahr

1 January 2011 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
MZManon C Zweers
Manon C Zweers
TBTineke N de Boer
Tineke N de Boer
JRJoel A.G. van Roon
Joel A.G. van Roon
JBJohannes Wj Bijlsma
Johannes Wj Bijlsma
FLFloris Pjg Lafeber
Floris Pjg Lafeber
SMSimon C. Mastbergen
Simon C. Mastbergen
Osteoarthritis (OA) is a degenerative joint disease characterized by progressive loss of articular cartilage, subchondral bone sclerosis, osteophyte formation, and synovial inflammation, causing substantial physical disability, impaired quality of life, and significant health care utilization. Traditionally, non-steroidal anti-inflammatory drugs (NSAIDs), including selective cyclooxygenase (COX)-2 inhibitors, have been used to treat pain and inflammation in OA. Besides its anti-inflammatory properties, evidence is accumulating that celecoxib, one of the selective COX-2 inhibitors, has additional disease-modifying effects. Celecoxib was shown to affect all structures involved in OA pathogenesis: cartilage, bone, and synovium. As well as COX-2 inhibition, evidence indicates that celecoxib also modulates COX-2-independent signal transduction pathways. These findings raise the question of whether celecoxib, and potentially other coxibs, is more than just an anti-inflammatory and analgesic drug. Can celecoxib be considered a disease-modifying osteoarthritic drug? In this review, these direct effects of celecoxib on cartilage, bone, and synoviocytes in OA treatment are discussed.